Atreca, Inc. (0C1.F)

0,0435 0,0000 (0,00%) Börsenschluss: 09:58PM CEST

Atreca, Inc.

835 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 595 2595
https://www.atreca.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 90

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John A. Orwin M.B.A.	President, CEO, Director & Principal Financial Officer	869,13k	N/A	1965
Dr. Tito A. Serafini Ph.D.	Founder & Director	623,94k	N/A	1963
Mr. Rick Ruiz	Principal Accounting Officer	N/A	N/A	1964
Ms. Courtney J. Phillips J.D.	General Counsel & Corporate Secretary	N/A	N/A	1975
Roger Richard Ruiz	Vice President of Finance	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Corporate Governance

Atreca, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 10, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.